Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease  by Lens, Sabela et al.
RE
p
S
L
a
A
R
A
A
K
A
C
H
L
1
a
m
m
t
a
a
c
p
H
t
p
e
c
p
h
1Digestive and Liver Disease 46 (2014) S197–S205
Contents lists available at ScienceDirect
Digestive  and  Liver  Disease
jou rna l h om epage: www.elsev ier .com/ locate /d ld
eview  Article
fﬁcacy  of  new  direct  acting  antivirals  in  transplant  recipients  and
atients  with  advanced  disease
abela  Lens,  Zoe  Marin˜o,  Xavier  Forns ∗
iver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 4 August 2014
ccepted  6 October 2014
vailable  online 6 November 2014
eywords:
ntiviral treatment
irrhosis
epatitis C
iver  transplantation
a  b  s  t  r  a  c  t
The  development  of new  direct  acting  antivirals  constitutes  a clinical  revolution  in the  ﬁeld  of  hep-
atitis  C  therapy  and,  most  probably,  in  the  history  of  Hepatology.  Difﬁcult-to-treat  patients,  such  as
cirrhotics  or patients  in  the peri-transplant  setting,  will clearly  beneﬁt  from  these  therapies,  particularly
from  interferon-free  all-oral  combinations.  However,  despite  the  substantial  improvement  of  the  hep-
atitis  C  drug  market,  access  to  these  therapies  will  likely  be  different  around  the  world  due  to economic
restrictions.  This  review  aims  to  clarify  the  current  stage  of  different  antiviral  strategies  (with  or  without
interferon)  in  these  difﬁcult  populations  by  analysing  speciﬁc  efﬁcacy  and  safety  results  in patients  with
cirrhosis,  patients  on  the  waiting  list  for liver  transplantation  and  recipients  with  hepatitis  C  recurrence
after  liver  transplantation.  Hitherto,  some  important  challenges  still remain  unanswered  in  these  patients
and  will  need  to  be assessed  in clinical  practice,  such  as the  evaluation  of  safety  and  efﬁcacy  in advanced
cirrhotic  patients  with  portal  hypertension,  the  impact  (if any)  of  viral  clearance  on clinical  outcomes  in
patients  with  decompensated  liver  disease,  the  role  of ribavirin  in all-oral  combinations,  the  relevance
of  the  development  of  multi-drug  viral  resistant  strains  and  the drug–drug  interaction  proﬁles  of these
drugs,  especially  after liver  transplantation.
©  2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
D lice. Introduction
In the last few years, the development and use of direct-acting
ntivirals (DAAs) have been a major step forward in the manage-
ent of chronic hepatitis C (HCV). Several combinations of new
olecules have been reported to cure more than 90% of hepati-
is C infections in many different patient populations in Phase-2
nd 3 trials, with and without pegylated interferon- (PEG-IFN)
nd/or ribavirin (RBV). The safety and efﬁcacy proﬁle of these DAA
ombinations is particularly relevant in so-called difﬁcult-to-treat
atients, namely those with advanced liver disease and those with
CV recurrence after liver transplantation (LT). Interferon con-
aining therapies are frequently contraindicated in this group of
atients, and previous antiviral regimens resulted in a very low
fﬁcacy and poor tolerance. This review aims to summarize the
urrent status and strategies regarding antiviral therapy in these
atients.
Open access under CC BY-NC-N∗ Corresponding author. Tel.: +34 93 227 5753; fax: +34 93 227 1779.
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590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. O2. Efﬁcacy of new DAAs in patients with advanced disease
2.1.  Compensated cirrhotic patients
2.1.1. Interferon-based therapy
Patients with chronic hepatitis C and advanced cirrhosis are one
of the most difﬁcult-to-treat populations, and at the same time they
are at high risk of developing decompensation or hepatocellular
carcinoma (HCC). Interferon-based therapy can only be adminis-
tered in cirrhotics with good liver function, and efﬁcacy results are
far from optimal, especially in genotype 1 patients (GT1). How-
ever, IFN-free regimens are not yet available or efﬁcacious enough
in some subsets of patients and, in addition, these all-oral com-
binations are usually more expensive. Therefore, IFN containing
regimens will remain as ﬁrst-line therapies in some settings, at
least, in the short term.
The  addition of ﬁrst-generation protease inhibitors (PI),
boceprevir and telaprevir, to pegylated interferon and ribavirin (PR)
has clearly been associated with an increase in response rates in
GT1 infected patients. Sustained virological response (SVR) rates
nse.increase by nearly 30% with triple therapy as compared to PR in
naïve patients and by 25–60% in treatment-experienced patients
(depending on previous treatment response) [1–5]. Nonetheless,
PI-based regimens in real-life compensated cirrhotics may be
pen access under CC BY-NC-ND license.
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Fig. 1. (A) Results of treatment strategies with sofosbuvir, simeprevir and
daclatasvir  in naïve cirrhotic patients. IFN-based: SOF + PR: sofosbuvir plus pegy-
lated interferon and ribavirin during 12 weeks, genotype 1 (NEUTRINO study)
[8]. DCV + PR: daclatasvir (12–24 w)  plus pegylated interferon and ribavirin (RGT
24–48 w), genotypes 1 and 4 (COMMAND-1) study [16]. SMV  + PR: simeprevir (12 w)
plus pegylated interferon and ribavirin (RGT 24–48 weeks), genotype 1 (pooled data
of QUEST-1, QUEST-2) [10,11]. IFN-free: SOF + RBV: sofosbuvir plus ribavirin in GT2
and 3: pooled data of FISSION and VALENCE studies [8,26–28]. SOF + DCV ± RBV:
sofosbuvir  plus daclatasvir with or without ribavirin 12–24 weeks in genotypes
1–3  [20]. SOF + SMV  ± RBV: sofosbuvir plus simeprevir with or without ribavirin
for  12–24 weeks in genotype one patients [19]. (B) Results of treatment strate-
gies  with sofosbuvir, simeprevir and daclatasvir in treatment-experienced cirrhotic
patients. IFN-based: SMV  + PR: simeprevir (12 w)  plus pegylated interferon and riba-
virin (24–48 weeks), genotype 1 (pooled data of PROMISE, ASPIRE and ATTAIN
studies)  [13–15]. IFN-free: SOF + RBV: sofosbuvir plus ribavirin in GT2 and 3: pooled
data of FUSION, POSITRON and VALENCE studies [8,26–28]. SOF + DCV ± RBV: sofos-
GT1–3, naïve or treatment-experienced (including PIs) received the
combination of SOF + DCV ± RBV 12–24 w [20]. SVR12 rates were198 S. Lens et al. / Digestive and L
ssociated with serious adverse events (SAEs), such as severe
nfections (4–6%), clinical decompensation (3–4%) and even death
6]. These serious side effects were not reported in the registra-
ion trials because patients included in these studies were mostly
ery well compensated cirrhotics without signiﬁcant portal hyper-
ension (low platelet count <90,000 for telaprevir and <100,000
or boceprevir was an exclusion criterion). The main predictive
actors of severe complications in cirrhotics undergoing triple ther-
py (severe infections, clinical decompensation or death) were a
ow platelet count (<100,000/mm3) and low serum albumin lev-
ls (<35 g/L) [6,7]. Importantly, the risk for severe complications
as 44% in patients with both factors, as compared to 3.4% in
atients with normal platelet count and serum albumin levels
6].
With the current approval of sofosbuvir and simeprevir in the
S and Europe, and the recent approval of daclatasvir in September
014, new interferon-based combinations will be available for eli-
ible cirrhotic patients.
Sofosbuvir  (SOF) is a nucleotide analogue with potent activ-
ty against HCV genotypes 1–6. The combination of PR plus SOF
00 mg/d for 12 weeks seems to offer the highest efﬁcacy and
he best safety proﬁle. This regimen was evaluated in the NEU-
RINO Phase-3 trial in treatment-naïve GT1, 4, 5 and 6 patients
mainly GT1) [8] providing an overall SVR rate of 90%. Cirrhotic
atients (n = 54) had a lower SVR rate than non-cirrhotics (80%
ersus 92%, respectively). Regretfully, data on interferon-based
herapy in treatment-experienced cirrhotics are only available in
 small number of GT2 and GT3 infected patients, with SVR rates
ver 80% [9].
Simeprevir (SMV) is a once-daily dosed NS3/4A protease
nhibitor with the added beneﬁt of a more convenient dose reg-
men and a more favourable side-effect proﬁle. Phase-3 trials in
aïve patients QUEST1 [10] and QUEST 2 [11] assessed the com-
ination of SMV  for 12 weeks and PR (response-guided therapy
4–48 w). Pooled data demonstrated overall SVR12 rates of 60% in
atients with cirrhosis (n = 48) compared to 82% in patients with-
ut cirrhosis and to 34% in the placebo group [12]. The PROMISE
13], ASPIRE [14] and ATTAIN [15] studies assessed the efﬁcacy of
he combination SMV  with PR in treatment-experienced patients;
he number of cirrhotic patients included in each study receiv-
ng SMV  was 39, 73 and 88, respectively. Pooled data showed
VR rates of ∼50%, higher in previous relapsers to PR (74%)
han in partial or null responders, as expected. It should be
oted that in the package insert, testing the Q80K mutation prior
o initiating SMV  treatment is recommended in patients with
T1a due to the lower chance of response if the mutation is
resent.
Daclatasvir (DCV) is a ﬁrst-in-class HCV NS5A replication
omplex inhibitor. The Phase-2b COMMAND [16] study evalu-
ted the efﬁcacy of the combination of DCV + PR in GT1 and
T4 naïve patients. Patients were randomly assigned to receive
CV 20 or 60 mg  or placebo once daily in combination with
R. At Week 12, DCV recipients achieving protocol-deﬁned
esponse  were re-randomized to continue triple therapy for a
otal duration of 24 weeks (24 triple) or to continue therapy
ith placebo + PR during weeks 13–24 (12 triple + 12). SVR12
ates were 8/13 (62%) and 4/7 (57%) in GT1 cirrhotic patients
n 20 or 60 mg,  respectively, compared with 2/8 (25%) receiv-
ng PR. The COMMAND-GT2/3 study assessed the combination
f DCV + PR 12–16 w in GT2 and 3 patients. Only 11 patients
ith cirrhosis (all GT3) were included. More frequent relapses
ccurred in cirrhotics (4/11, 36%) than in non-cirrhotics (8/39, 21%)
17].
Efﬁcacy results in cirrhotic patients treated with PR plus sofos-
uvir, simeprevir or daclatasvir are summarized in Fig. 1A (naïve)
nd B (treatment-experienced).buvir plus daclatasvir with or without ribavirin 12–24 weeks in genotypes 1–3 [20].
SOF + SMV  ± RBV: sofosbuvir plus simeprevir with or without ribavirin for 12–24
weeks  in genotype one patients [19].
2.1.2. Interferon-free therapies
2.1.2.1.  Genotype 1 cirrhotic patients. For GT1 cirrhotics, the com-
bination of SOF and RBV for 24 w appears to be suboptimal. In
the group of 13 patients with advanced ﬁbrosis (F3/4) [18], SVR
rates were 50% and 29% in weight-based and low-dose RBV, respec-
tively. Data from Phase-2 studies strongly suggest that the addition
of simeprevir or daclatasvir to sofosbuvir (with or without RBV)
signiﬁcantly increases SVR rates up to 90% (Fig. 1A and B). The com-
bination of SOF + SMV  ± RBV 12–24 w in cohort 2 of the COSMOS
study [19] evaluated 41 GT1 patients with F3–F4 scores who  were
prior null-responders or naïve. Preliminary data indicated that rates
of SVR at week 4 were 100% (7 of 7 and 12 of 12 with and with-
out RBV, respectively) in treatment-naïve patients, and 100% (7 of
7) and 93% (14 out of 15) with and without RBV, respectively, in
prior null responders. Thirty-two patients with signiﬁcant ﬁbrosis,>95%, although speciﬁc analysis in the cirrhotic population is not
available.
S. Lens et al. / Digestive and Liver D
Fig. 2. Results of forthcoming DAA combinations in naïve and treatment-
experienced  cirrhotic patients (all genotype 1). SOF + LDV ± RBV: sofosbu-
vir/ledipasvir  ﬁxed dose combination with or without ribavirin for 12–24 w (pooled
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sata of ION-1 and ION-2 studies) [21,22]. Paritaprevir + Ombitasvir + Dasabuvir dur-
ng 12–24 w (TURQUOISE II) [23]. DCV + ASV: daclatasvir plus asunaprevir during
4  w in genotype 1b patients [24].
Other drugs are likely to be approved later in 2015; these include
he ﬁxed dose combination of sofosbuvir and ledipasvir (LDV), the
riple combination of co-formulated paritaprevir, ombitasvir plus
asabuvir, and the protease inhibitor asunaprevir (ASV). The main
esults of the registered trials with these molecules are summarized
elow and in Fig. 2.
Two  registered Phase-3 studies have assessed the safety and
fﬁcacy of SOF and LDV (with or without RBV) for 12 versus
4 weeks in GT1 infected patients. In the ﬁrst study (ION-1),
hich included naive patients, there were 136 cirrhotics and SVR
ates were 100% in the RBV arms and 97% in the non-RBV arms
21]. In the second study (ION-2), which included treatment-
xperienced patients (with a signiﬁcant number of failures to
I), there were 88 cirrhotics: SVR rates were 100% in the 24-
eek regimen, but the ﬁgure decreased to ∼85% in the 12-week
rms [22]. The latter suggests that a regimen containing sofos-
uvir and ledipasvir is excellent in compensated cirrhotics and
xtension of treatment to 24 weeks may  be necessary in previous
on-responders.
A large randomized clinical trial (TURQUOISE-II) performed
peciﬁcally in cirrhotic patients with an all-oral DAA combina-
ion has recently evaluated the safety and efﬁcacy of paritaprevir
oosted with ritonavir, ombitasvir and dasabuvir co-administered
ith RBV for 12 or 24 weeks in HCV GT1 infected patients (both
reatment-naïve and -experienced) [23]. SVR rates reached 92%
nd 96% in the 12-week and 24-week arms, respectively. A trend
owards slightly lower SVR rates were observed in GT1a previ-
us null responders, as well as in patients with more signiﬁcant
ortal hypertension (platelets <100,000/mm3) or more advanced
irrhosis (albumin <35 g/L) in the 12-week arm.
A  combination of daclatasvir and asunaprevir for 24 weeks was
valuated in 223 GT1b cirrhotics; SVR rates were 91% in naïve, 81%
n ineligible/intolerant patients and 87% in treatment-experienced
ndividuals [24].
Preliminary data on the Phase-2 C-WORTHY study [25]
ere presented at the latest EASL meeting. Treatment-naïve
atients  with cirrhosis or null responders were randomized
o receive MK-5172 (PI, 100 mg/d) and MK-8742 (NS5A com-
lex inhibitor, 50 mg/d) with or without RBV (weight-based)
or 12 or 18 weeks. Around 96% of cirrhotic patients (n = 164)
chieved undetectable RNA levels on treatment, reﬂecting the
otency of the combination. Final data on SVR rates are expected
oon.isease 46 (2014) S197–S205 S199
2.1.2.2. Non-genotype 1 cirrhotic patients. For GT2 and 3-infected
patients, SOF 400 mg/d plus RBV represents the only active treat-
ment available. Results from four Phase 3 trials assessing this
combination have been published (FISSION, FUSION, POSITRON
and VALENCE). Overall, SVR rates in GT2 were consistently lower
in cirrhotics compared to non-cirrhotics, but 12 or 16-week regi-
mens achieve SVR rates of around 80% [8,26]. In GT3 patients, it
became clear that a 12-week regimen of SOF and RBV was insufﬁ-
cient for cirrhotic patients, and treatment extension up to 24 weeks
increased SVR rates to 92% in naïve patients and to 62% in previous
non-responders to PR [8,27,28].
Sofosbuvir, simeprevir, ledipasvir, daclatasvir, paritaprevir and
ombitasvir also have antiviral effectiveness against GT4 [29].
Sofosbuvir is also effective for GT5 and 6. However, for GT4–6
infected patients there are very little data on interferon-free regi-
mens, and no solid recommendations can be given in case of
cirrhosis.
2.2. Decompensated cirrhotic patients
In the era of interferon-free oral combinations, cirrhotic patients
with more advanced liver disease in whom IFN-based therapy is
contraindicated may  be candidates for antiviral therapy. Nonethe-
less, data on the potential impact of signiﬁcant portal hypertension
in the achievement of SVR are lacking. On the other hand, the
impact of SVR in patients with decompensated cirrhosis may  be
heterogeneous, since it encompasses a wide spectrum of disease,
ranging from patients with relatively well-preserved liver function
(mild ascites or recent variceal bleeding) to patients with very poor
liver function and a short life expectancy (Child–Pugh C > 10 points)
[30,31]. Several studies have found that ﬁbrosis regression/reversal
might be more likely in early cirrhosis than established cirrhosis
and that the absence of portal hypertension may  be a determinant
of reversibility [32].
Hitherto,  most studies have included very well compensated
cirrhotic patients probably with, although not measured, a low
degree of portal hypertension. Indeed, in the Phase-3 Turquoise
II study [23] the median platelet count (as an indirect marker of
portal hypertension) was 140,000/mm3 (n = 380); and in the stud-
ies evaluating the combination of sofosbuvir and ledipasvir [21,22]
less than 5% of the cirrhotic patients included (n = 224) had platelet
counts below 90,000/mm3.
Preliminary data are available in a small cohort of 25
compensated or decompensated cirrhotic patients with portal
hypertension (mean HVPG 16.9 mmHg) who were randomized to
sofosbuvir and ribavirin for 48 weeks, versus an observational
arm (after 6 months these patients crossed over to the treatment
arm) [33]. From a virological point of view, it was interesting to
learn that at weeks 2 and 4 after treatment initiation, 56% and
100% of Child–Pugh A patients had undetectable HCV-RNA; ﬁg-
ures for Child–Pugh B patients were only 44% and 75%, respectively.
This might be explained by changes in drug PK; sofosbuvir expo-
sure was 2-fold higher in HCV-infected patients without hepatic
impairment, compared with patients with advanced liver disease
[34]. Regarding clinical outcomes, after a 24-week period, the data
suggest a reduction of clinical events in patients included in the
treatment arm, but importantly, data on portal pressure were
not yet available. From a safety point of view, exposure to some
new compounds (such as paritaprevir [35], asunaprevir [36] and
simeprevir [37]) is signiﬁcantly increased in Child–Pugh C patients
and its use is currently not recommended until more data are
available. Whether achieving SVR in patients with decompensated
cirrhosis is associated with a further reduction in HVPG and protec-
tion from liver decompensation, and, ﬁnally, lower mortality, needs
to be investigated.
S200 S. Lens et al. / Digestive and Liver Disease 46 (2014) S197–S205
Table 1
Ongoing clinical trials including cirrhotic patients and hepatitis C Virus transplant recipients.
Identiﬁer Regimen Treatment duration Genotype Child–Pugh class Trial Phase
NCT01938430 SOF + LDV + RBV 12–24 w 1,4 Pre-LT: B, C
Post-LT:  A, B, C
2
NCT01973049 DCV + ASV + BMS-
791325 ± RBV
12 w 1 A 3
NCT02032875 DCV + SOF + RBV 12 w 1–6 Pre- & post-LT: A 3
NCT02115321 MK-5172 + MK-8742 12 w 1,4–6 B 2
NCT02105454 MK-5172 + MK-
8742 + RBV
12  w 1 A 2
NCT02114151 MK-5172 + MK-8742 12 w 1,4–6 A 3
NCT01909804 SOF + GS-5816 + RBV 12 w 3 A 2
NCT01962441 SOF + RBV 16–24 w 2,3 A 3B
NCT01938625 SMV  + DCL + RBV 24 w 1b Post LT
Metavir F1-F4 (Child A)
2
NCT01782495  Paritaprevir/Ombitasvir
(ABT-267) + Dasabuvir
12 w 1 Post LT
Metavir F1-F3 (no
2
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GT1 cirrhotic patients awaiting LT are anecdotic. Verna et al. [53]
reported preliminary results of triple therapy in a very small cohort
of 29 HCV-infected cirrhotic patients on the waiting list for LT (Child
Fig. 3. Results of treatment strategies within the peri-transplant setting. Pre-LT
treatments: Treatments while on the waiting list. PR: PEG-interferon plus riba-
virin up to liver transplantation (LT) [48–52], PR + PI: PR plus protease inhibitor
[53],  SOF + RBV: sofosbuvir 400 mg/d plus ribavirin up to 48 weeks or LT. SVR12
rates  are referred to undetectable HCV RNA 12 weeks after LT [54]. Silibinin
monotherapy  is not showed (SVR12, 0%) [55]. Post-LT treatments: PR: PEG-
interferon plus ribavirin for 48 weeks (historical cohort), PR + PI: PR plus protease
inhibitor  (telaprevir or boceprevir) for 48 weeks (* pooled data from case stud-
ies  and REPLACE study) [72,82], SOF + RBV: sofosbuvir 400 mg/d plus ribavirin for
24 weeks [83], SOF + RBV (+IFN): sofosbuvir 400 mg/d plus ribavirin (with or with-(ABT-333) ± RBV
,  weeks; SOF, sofosbuvir; LDV, ledipasvir; RBV, ribavirin; LT, liver transplantation
Other studies assessing the efﬁcacy of interferon-free combina-
ions in patients with cirrhosis are currently ongoing (Table 1).
.  Efﬁcacy of new DAAs in the peri-transplant setting
HCV-related cirrhosis constitutes the leading indication for LT
n the Western world and Japan [38]. Unfortunately, HCV infec-
ion of the new graft occurs in all patients with detectable viraemia
t the moment of LT [39]. The main characteristic of HCV recur-
ence after LT is the accelerated course of the disease [40–44].
n fact, ﬁbrosis progression in the transplant population has been
stimated to be 2–4 times faster than the HCV-infected immune
ompetent patients [45]. This accelerated ﬁbrosis rate negatively
mpacts both on the allograft and recipient survival, which are sig-
iﬁcantly reduced in HCV recipients when compared to non-HCV
ransplanted patients [40,44,46].
Preventing the allograft HCV infection by eradicating the virus
efore LT is the best strategy to avoid HCV recurrence and its con-
equences after LT. However, HCV-infected patients enlisted for
ransplantation are often the sickest, and the waiting list exhibits
ome peculiarities that may  hamper the applicability of these
ntiviral therapies. In those patients in whom treating pre-LT is
ot feasible, and who develop viral recurrence after LT, eradicating
he virus after LT is the only alternative. The different HCV thera-
ies speciﬁcally evaluated in the LT setting, both before or after LT,
re summarized in Fig. 3 and will be discussed herein.
.1. Antiviral treatment before LT: the waiting list
Two clinically different patterns of enlisted patients have to
e considered for the purposes of HCV treatment. This difference
ill be relevant in terms of virological response, safety proﬁles
nd pharmacokinetics. Firstly, patients in whom the indication for
T is the development of HCC often have compensated cirrhosis
nd preserved liver function. The second group would be those
atients with decompensated cirrhosis, who exhibit progressive
iver impairment. With the new DAAs, treatment of patients on the
aiting list is expected to radically change in the coming years.
owever, it is relevant to mention the results of all the different
ntiviral regimens used in this population to date.
.1.1. Interferon-based regimens
Interferon-based therapy has been shown to be suboptimal in
atients awaiting LT from both virological and safety perspectives.
nterferon can only be administered in cirrhotic patients with good
iver function (Child–Pugh ≤ 7 or MELD ≤ 18) (on the waiting list,cirrhotics  allowed)
 daclatasvir; ASV, asunaprevir; SMV, simeprevir.
typically  referred to patients in whom the indication for LT is HCC)
[47]. In those patients with more advanced disease, IFN should
not be used, since SAEs (i.e. bacterial infections [48], grade 3 and
4 cytopenias and clinical decompensation) have been shown to be
frequent and potentially life threatening. However, prevention of
graft HCV infection was shown to be feasible in different studies
some years ago, in those patients on the waiting list who achieved
undetectable HCV-RNA when PR was  administered [48–51].
Global virological responses, maintained after LT, were around 25%
(slightly higher, as expected, in HCV GT2/3 or patients with IL28B
CC genotype) [52], but safety proﬁles were poor.
Data on PIs-based therapy (boceprevir or telaprevir plus PR) inout interferon) (Cˆompassionate  use in severe HCV recurrence including FCH) [84],
Paritaprevir + Ombitasvir + Dasabuvir + RBV: Paritaprevir/ritonavir plus ombitasvir
plus  dasabuvir plus ribavirin for 24 weeks (** patients included had ﬁbrosis stage
Metavir F0-2). SVR12 rates refer to undetectable HCV RNA 12 weeks after the end
of treatment [79].
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 62%, Child B 38%). Overall SVR12 was 52%; 67% when considering
nly those who underwent LT (n = 12). However, SAEs were fre-
uent (31%) and included one death (3%) and 8 hospitalizations
28%). Moreover, SVR rates with PIs-based therapy are very low in
irrhotic patients who are previous null responders to PR, a com-
on situation in patients awaiting LT. Therefore, in real life, the
roportion of patients on the waiting list that may  beneﬁt from
riple therapy with telaprevir or boceprevir is very small.
Importantly, with the recent approval of the new DAAs (sofos-
uvir, simeprevir, and daclatasvir), the use of boceprevir and
elaprevir are no longer recommended in this population, due to
heir poor safety proﬁle [29].
.1.2. IFN-free regimens
Very  little data are available to date for use of IFN-free regi-
ens on patients on the waiting list. Fortunately, as previously
entioned, some clinical trials are currently evaluating different
ombinations in this patient population (Table 1), and we will pre-
umably have results soon.
Sofosbuvir  and ribavirin
This  combination was the ﬁrst all-oral IFN-free regimen with
DAAs  to be assessed in patients awaiting LT. A Phase-2 open-
label  study was conducted, in which 61 HCV-infected patients
(GT1–4)  awaiting LT received sofosbuvir and ribavirin until LT
or  up to 48 weeks [54]. The indication for LT was  HCC; nearly
75%  of patients were Child–Pugh A, all had MELD score below
15  and most individuals were previous non-responders to IFN-
based  regimens (75%). The median duration of therapy was  17
weeks.  Forty-six patients underwent LT and of these, 43 (92%) had
HCV-RNA < 25 IU/mL at time of LT. Of these, 42 reached 12 weeks
of  follow-up after transplantation and 29 (69%) remained free of
recurrence and reached SVR12. The strongest predictor of post-LT
SVR  was the number of consecutive days with undetectable HCV
RNA  prior to transplant. Treatment with SOF + RBV was generally
well  tolerated. These results are encouraging. Longer treatment
duration  and/or the addition of a second DAA (currently under
evaluation  with ledipasvir, see Table 1) may  reduce the rate of
virological  failures.
Silibinin
Some  years ago, the antiviral efﬁcacy of silibinin monother-
apy  for patients awaiting LT was explored in a proof-of-concept
Phase-2 trial [55], as this natural ﬂavonoid has been shown to
exert  potent antiviral properties [55–57]. The study included
a  very small number of patients (n = 14), but demonstrated a
consistent  antiviral effect of intravenous silibinin and a good
safety  proﬁle in these very ill patients (43% Child A, 57% Child
C).  Although some patients reached undetectable HCV-RNA dur-
ing therapy, none of them achieved SVR following LT. The main
problems  of this study were the short-treatment duration and
the  fact that the drug needs to be administered intravenously.
It  is unknown whether the use of silibinin could be helpful in
patients  treated with new DAAs on the waiting list and this could
be  explored in the future, especially considering the favourable
economic proﬁle of this drug.
Peculiarities of treatment while on the waiting list:
Relevance  of treatment duration before LT
As the moment of LT is unpredictable (unless when considering
living  donor LT recipients), one of the main difﬁculties of treating
patients  on the waiting list is to know when to start antiviral
treatment to guarantee a minimal effective duration. Different
studies  to date have shown the impact of treatment duration on
SVR rates after LT.isease 46 (2014) S197–S205 S201
Everson et al. [50] treated 56 well-compensated cirrhotic
patients on the waiting list with PR. In this study, the strongest
predictor of virologic response after LT was duration of treat-
ment.  In fact, SVR rates were signiﬁcantly higher (50%) in those
patients  who  received pre-transplant therapy for >16 weeks than
in those receiving <16 weeks and other historical treated cohorts
[48,49,51]  (although this speciﬁc analysis of treatment duration
was  not performed in these studies).
Treatment duration was  also relevant in another trial, in which
patients  on the waiting list were treated with sofosbuvir and riba-
virin  [54]. The strongest predictor of post-LT SVR for this IFN-free
combination was  the number of consecutive days with unde-
tectable  HCV RNA prior to transplant. In fact, only one relapse
occurred among the 25 individuals with undetectable HCV-RNA
for  >28 days while on treatment.
• Possibility  of delisting
Given  the short supply of organs available, a potential addi-
tional  beneﬁt of treating patients before LT would be to improve
liver  function, and perhaps regain compensation for ﬁnal delist-
ing.  This has been shown in some patients with HBV-related
cirrhosis treated with nucleo(s)tide analogues [58,59], but in
HCV-infected  cirrhotic patients this has not yet been demon-
strated  [60]. However, HCC patients will need a LT anyway, and
those  patients with severely impaired liver function are probably
less  likely to re-compensate.
• Relevance  of virological failures
Another distinct feature of patients awaiting LT is the potential
risk  of viral breakthrough or relapse during or after treatment,
which  may  theoretically induce ﬂares that could trigger liver
decompensation. It is thus extremely important to choose the
best  treatment combination (high potency and high genetic bar-
rier)  in order to minimize the possibility of virological relapse
or  the selection of resistant-associated viral strains (RAVs). The
ﬁtness  of resistant strains is usually lower than that of the wild-
type  viruses, which tend to replace RAVs progressively. This
issue  is important, since the potential presence of multi-resistant
strains may  hamper antiviral efﬁcacy if urgent treatment is
required.
3.2.  Antiviral treatment after LT
Recurrence of HCV after LT will be inevitable in viraemic
patients. If preventive treatment before transplantation fails or is
not possible, the graft will be immediately infected [39] and treat-
ment after LT will have to be considered.
3.2.1. Why  should we treat?
The  main characteristic of hepatitis C recurrence after LT,
as already mentioned, is the accelerated course of the dis-
ease [40,42–44,46,61,62]. The presence of signiﬁcant ﬁbrosis
beyond the portal tract (METAVIR F ≥ 2), portal hypertension
(HVPG ≥ 6 mmHg) or high liver stiffness (>8.6 kPa) one year after
LT accurately identify patients who are in urgent need of treatment
due to a higher risk for clinical decompensation and death [63,64].
In patients with a severe recurrence occurring during the ﬁrst
months after LT (i.e. ﬁbrosing cholestatic hepatitis, FCH), antiviral
therapy and viral clearance is critical, otherwise patients will die or
need re-transplantation.
Eradicating the virus after LT may  have beneﬁcial effects. Several
studies have shown a signiﬁcant histological improvement or sta-
bilization of ﬁbrosis after SVR in the transplant setting, compared to
non-responders [65,66]. Similarly, portal pressure measurements
and determinations of transient elastography also suggest the ben-
eﬁcial effect of antiviral treatment on liver ﬁbrosis when SVR is
achieved [66].
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.2.2. How can we treat?
.2.2.1.  Interferon-based regimens. The overall SVR rates with PR
re low; ranging between 30% and 40% across different series
65,67,68]. These modest virological results are mainly explained
y high rates of treatment discontinuation (20–38%) and dose
eductions (66–73%) due to adverse events. Liver transplant recip-
ents are prone to haematological toxicity, particularly anaemia,
hich is almost universal in these patients [69]. The risk of rejection
s small (∼5%) [70,71].
Regarding  triple therapy with PI in the post-LT setting, several
tudies have evaluated the safety and efﬁcacy of such regimens in
300 patients with hepatitis C recurrence [72–75]. Two  thirds of
hese received telaprevir and the rest were treated with bocepre-
ir. Most of the patients had an advanced ﬁbrosis (METAVIR F ≥ 2)
r FCH. Approximately half of the patients had received a previ-
us course of antiviral therapy. SVR rates ranged between 48% and
2% [72–75]. Despite the increased efﬁcacy, the major concern of
riple therapy in LT recipients is the high rate of SAEs leading to
reatment discontinuation. Drug–drug interactions (DDI) are an
dditional challenge when using telaprevir and boceprevir. First
eneration PIs are not only substrates, but also inhibitors of the
YP3A4 system, thus strongly interacting with many drugs. Due to
he narrow therapeutic range of cyclosporine and tacrolimus, dose
djustments are crucial and require very close monitoring when
ombined with PIs (Table 2, [37,76,77,69,78–81]).
The only Phase-3 clinical trial assessing the safety and efﬁcacy
f telaprevir in the liver transplant setting [82] was performed in
urope, and included 74 naïve patients with GT1 hepatitis C recur-
ence with a METAVIR score of F0–F3. Treatment consisted of 12
eeks of triple therapy, followed by 36 weeks of PR. Tacrolimus or
yclosporine doses were adjusted on telaprevir initiation and dis-
ontinuation. Final data from 61 of the 74 patients were available
nd presented in the last European Meeting, showing SVR rates of
7%. Eight (11%) patients had 11 SAEs, and there were no rejection
pisodes during the study period.
.2.2.2. Interferon-free regimens.
Sofosbuvir and ribavirin
Sofosbuvir  plus RBV is the ﬁrst interferon-free combination to
be evaluated for hepatitis C recurrence in a clinical trial [83]. A
pilot  single-arm study assessed the safety and efﬁcacy of sofos-
buvir  400 mg/d and RBV (dose escalating regimen starting at
400  mg/d) for 24 weeks in 40 patients with HCV recurrence (any
genotype)  at least 6 months after LT.
Of the 40 patients, 33 were infected with GT1. The study
included treatment-naïve and treatment-experienced patients
(some  even with PI); 40% were compensated cirrhotic patients.
Despite  these characteristics, all individuals had HCV RNA
<25  IU/mL at week 4 of treatment initiation. SVR12 was achieved
in  28 (70%) of the 40 patients (Fig. 3). These results can be con-
sidered  excellent, particularly due to the good tolerance; most
side  effects were mild and no rejection episodes occurred during
therapy.
Compassionate use of DAAs after LT
Results from 104 HCV-infected LT recipients included in the
Sofosbuvir  compassionate use programme were presented at
the last European meeting [84]. The antiviral regimen included
sofosbuvir  400 mg/d for up to 48 weeks, with appropriate doses
of  RBV. PEG-IFN was added at the investigator’s discretion. The
patients  included in this programme differed substantially from
those  included in the pilot study described above: approximately
half  of these patients had severe cholestatic hepatitis (some
of  them well-documented FCH) or were rapid ﬁbrosers; the
remaining  half had compensated or decompensated cirrhosis.
Sixty  patients (58%) presented an improved clinical conditionisease 46 (2014) S197–S205
(decrease of hepatic encephalopathy episodes and/or improve-
ment/disappearance of ascites). Although clinical improvement
was  subjectively assessed by the investigators, liver function
tests  improved remarkably over time. The other 23 patients
(22%)  remained stable, while in 21 (20%) the disease progressed
or  the patient died (n = 18). Of the 93 patients on which HCV-RNA
testing  was  carried out at the end of treatment, 76 (82%) had
undetectable HCV-RNA; 53 (62%) of 85 patients with more than
12  weeks of follow-up after LT achieved SVR. SAEs were fre-
quent,  but they were mostly attributable to disease progression.
Overall, the preliminary results of this programme indicate that
a  regimen containing sofosbuvir is able to inhibit hepatitis C
replication  in most patients, and that this is associated with an
improvement  in the clinical condition of a signiﬁcant number of
patients. Although longer follow-up is obviously needed, these
results  are encouraging. A particularly relevant result of this
study  was  the excellent response in patients with cholestatic
hepatitis (including FCH), in which liver tests improved signif-
icantly  only a few weeks after treatment initiation and viral
clearance. SVR in patients with acute cholestatic hepatitis/FCH
was  70%, whereas SVR in those with established cirrhosis was
48%  (Forns, personal communication). The latter strongly sug-
gests  the beneﬁt of early treatment in severe forms of hepatitis C
recurrence.
Data from a small compassionate use programme with sofos-
buvir  and daclatasvir were also recently presented [85]. This
study  included 12 GT1/4 recipients with severe HCV recurrence
(METAVIR F3–4, including 3 FCH) in whom PEG-IFN-based
therapy was  unfeasible, who were treated with sofosbuvir
400  mg/d and daclatasvir 60 mg/d either with or without RBV for
24 weeks. All patients achieving 12 and 24 weeks of treatment
had  undetectable HCV-RNA, although results of follow-up are
still  lacking. No adverse events were directly attributable to
the  drugs. In patients who  completed the treatment, mean
Child–Pugh score and serum albumin concentration showed a
signiﬁcant improvement compared to baseline.
• Paritaprevir, Ombitasvir plus Dasabuvir and ribavirin in HCV-
infected  LT recipients
In  this Phase-2 study [79] the safety and efﬁcacy of this
3-drug combination, plus ribavirin administered for 24 weeks,
were  assessed in 34 HCV-infected liver transplant patients.
The  included patients were GT1 infected, naïve after trans-
plantation and had mild ﬁbrosis in the graft (METAVIR ≤F2).
Preliminary analysis has shown that all 34 patients had unde-
tectable  HCV-RNA at end of treatment, and 25 (96%) of 26
with  sufﬁcient follow-up achieved SVR. The only patient
who  experienced relapse had RAVs (R155K in NS3 pro-
tease,  M28T + Q30R in NS5A, and G554S + G557R in NS5B);
none  of these mutations were present at baseline. Tolerance
of  this regimen was  good; no episodes of rejection were
reported.
A  number of other clinical trials, using different DAA combi-
nations  in the peri-transplant setting, are currently recruiting
patients and this is summarized in Table 1.
• Speciﬁc  features of interferon-free regimens in HCV-infected liver
transplant  recipients
Renal  failure is common in liver transplant recipients. Most
patients  have decreased glomerular ﬁltration rate (GFR) due (at
least in part) to the long-term use of cyclosporine or tacrolimus.
Sofosbuvir, for instance, is not recommended if GFR is below
30  ml/min [86].
Another issue that needs particular consideration in the LT
setting  is that these patients usually have high viral loads,
making it easier to select for drug resistant strains. The latter
might  be particularly relevant in those patients with FCH, who
exhibit  the highest viremias.
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Table  2
Drug–drug interactions between direct acting antivirals and calcineurin inhibitors.
DAA Cyclosporine Tacrolimus
Healthy
volunteers
Dose
adjustment
Healthy
volunteers
Dose
adjustment
Boceprevir [76,77]¥ AUC ↑ 2.7 fold ↓ 2 fold AUC ↑ 17 fold ↓ 5 fold
Telaprevir  [77,69]¥ AUC ↑ 4.6 fold ↓ 4 fold AUC ↑ 70 fold ↓ 35 fold
Paritaprevir  [79] AUC ↑ 5.8 fold ↓ 5 fold AUC ↑ 58 fold ↓ 100 fold
Simeprevir  [37] AUC ↑ 19% Under
investigation.
Not
recommended
AUC  ↓ 17% Not necessary
Sofosbuvir  [80]¥ No change Not necessary No change Not necessary
Daclatasvir  [81] No  change Not necessary No change Not necessary
¥ AUCinf is given AUCLast is given.
DAA, direct acting antiviral; AUC, area under curve.
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.2.3. When should we treat?
The most common approach to treat hepatitis C after LT so far
as been to start antiviral therapy once the histological damage
in particular liver ﬁbrosis) is conﬁrmed in the graft. This assump-
ion was made in the interferon era, in which treatment in the
ery early phases of LT was not recommended for different rea-
ons. In the early period after LT, individuals are still under strong
mmunosuppression, at risk of opportunistic infections, not uncom-
only recovering or being treated for surgical complications and
ndergoing treatment with multiple drugs.However, with the new DAAs, this recommendation will prob-
bly need to be reviewed. Although caution is needed, experiences
o date regardingtreatments with DAAs of very early severe HCV
ecurrences (i.e. FHC) suggest that treatment is feasible and safe <90,000 or HVPG >10 mmHg or large oesophageal varices. *Rapid ﬁbrosers referred
ne year after LT. In red: scarce data is available.
at  very early phases after transplantation. In addition, fortunately
the many new anti-HCV compounds do not seem to have clinically
signiﬁcant interactions with cyclosporine and tacrolimus, which
makes treatment much easier (Table 2).
4. Conclusions
In 2014 and 2015, the new IFN-containing and IFN-free
regimens will become available. Starting in 2015 and onwards,
IFN-based therapies will be replaced by all-oral DAA combinations,
especially in difﬁcult-to-treat populations, and at least in those
areas of the world in which these molecules have been approved
and are affordable (Fig. 4). However, despite a large HCV drug
market, treatment options will likely be very different, depending
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